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ABSTRACT
Objective To review and critically appraise the ocular 
manifestation and the presence of SARS- CoV-2 through 
PCR positivity from ocular samples in COVID-19- related 
patients. Moreover, to evaluate the time and severity 
association of ocular manifestation to systemic disease of 
COVID-19.
Methods and analysis A systematic literature 
search from PubMed, ScienceDirect and Google Scholar 
databases was performed using standardised Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses guideline. Selected keywords were related 
to COVID-19, ocular manifestation and PCR testing of 
SARS- CoV-2. Studies were assessed for their validity, and 
the data were extracted by two independent reviewers. 
Observational, case series and case report studies were 
included if they met the selection criteria. Meta- analysis 
was performed to estimate the pooled prevalence of ocular 
manifestations and PCR positivity from tears.
Results Thirty- one articles were qualitatively reviewed, 
and 14 studies were included in the meta- analysis. The 
pooled prevalence of ocular manifestation among COVID-
19- related patients was 0.05 (95% CI 0.02% to 0.08). The 
overall PCR from tears samples positivity rate from COVID-
19- related patients presenting with ocular manifestation 
was 0.38 (95% CI 0.14% to 0.65). Ocular manifestation 
could precede systemic manifestation in about 0.28 (95% 
CI 0.05% to 0.58) of COVID-19- related patients with ocular 
manifestations. Besides, ocular manifestation was not 
associated with a severe form of COVID-19.
Conclusion Although the overall number of ocular 
manifestation and SARS- CoV-2 PCR positivity rate from 
ocular samples was very low, around a quarter of COVID-
19- related patients with ocular manifestation presented 
their ocular manifestation earlier than the systemic 
manifestation regardless of the severity. Interestingly, 
SARS- CoV-2 PCR was positive from one- third of ocular 
samples, which could potentially be the source of infection 
to the respiratory tract and the environment, although the 
infectivity is yet to be determined.
INTRODUCTION
The 2019 novel coronavirus (2019- nCoV) or 
SARS- CoV-2, a single- stranded positive- sense 
RNA virus, belongs to the family of Coro-
naviridae. COVID-19, the disease caused 
by SARS- CoV-2 infection, can range from 
being asymptomatic to critically ill, leading 
to death.1 2 In December 2019, SARS- CoV-2 
started to spread, and COVID-19 had become 
a global pandemic. By 14 May 2020, it was 
estimated that more than four million people 
being infected and 294 046 deaths worldwide 
were caused by COVID-19.3 WHO issued 
the first set of personal protective equip-
ment guideline in March 2020 based on the 
previous experience in managing Middle 
Eastern respiratory syndrome coronavirus 
and SARS- CoV in 2004.4 In their recommen-
dation, wearing goggles or face shield was 
included as a protection against SARS- CoV-2 
transmission, even though there was still lack 
of published studies reporting eye infection 
caused by COVID-19 at that time. From the 
previous SARS- CoV experience, corona-
virus could be found in tears, based on PCR 
Key messages
What is already known about this subject?
 ► SARS- CoV-2 can infect and replicate in the eyes 
through angiotensin receptor enzyme-2 receptor 
found in conjunctiva and cornea.
 ► Conjunctivitis among patients with COVID-19 had 
been reported.
 ► The nasolacrimal duct can transmit the virus from 
the eyes to the nasopharynx.
What are the new findings?
 ► The overall prevalence of ocular manifestation 
among patients with COVID-19 is 5%.
 ► Around a quarter of ocular manifestation could pre-
cede systemic manifestations among COVID-19- 
related patients with ocular manifestation.
 ► SARS- CoV-2 PCR was positive from one- third of oc-
ular samples among COVID-19- related patients with 
ocular manifestation.
How might these results change the focus of 
research or clinical practice?
 ► Conjunctivitis in patients suspected to have 
COVID-19 could potentially be the source of infection 
due to SARS- COV-2.
 ► Detecting SARS- CoV-2 from ocular samples is dif-
ficult. Yet, ophthalmologists or general practitioners 
facing conjunctivitis in patients highly suspected to 
have COVID-19 or in areas with high transmission of 
COVID-19 should wear adequate personal protective 
equipment, including mask and goggles/face shield.
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positivity.5 Human- to- human aerosol transmission has 
been described mainly via the respiratory tract through 
droplets.1 2 However, the possibility of SARS- CoV-2 trans-
mission through the ocular surface in the population is 
maybe often overlooked.
Lu et al6 warned that ocular manifestation may have 
appeared earlier than predicted. Their argument was based 
on the report of Guangfa Wang, a member of the national 
expert panel who inspected Wuhan and then got infected 
by SARS- CoV-2 at the beginning of the COVID-19 spread. 
Wang described that his red eyes had started several days 
before respiratory symptoms of COVID-19 appeared. As it 
may appear earlier, the ocular manifestation may be under- 
reported. Guan et al,7 in their first report of a COVID-19 
patient in China, found that ocular manifestation only 
contributed in around 1% of patients. Subsequently, Wu 
et al8 reported that ocular manifestation might be as high 
as 30% among patients with COVID-19. In comparison to 
lung and bronchial tissue cultures, the highest viral replica-
tion of SARS- CoV-2 at 48 hours was found in conjunctival 
tissue culture based on the recent ex vivo study.9 More-
over, SARS- CoV-2 PCR from tears can be still positive up to 
3 weeks from the onset of systemic symptom even though 
the nasopharyngeal swab result is already negative.10 As 
SARS- CoV-2 replication in ocular surface may continue for 
a relatively long period and the virus can be transported to 
nasopharyngeal mucosa through the nasolacrimal duct,11 
there is a possibility that ocular manifestation can affect 
systemic COVID-19. With the growing number of recently 
published studies, we performed a systematic review and 
meta- analysis to elaborate the possibility of the eye as an 
infection source for systemic COVID-19 by looking at the 
ocular manifestation and the presence of SARS- CoV-2 in 
the eye. We also aimed to describe the ocular clinical mani-
festation and the onset of ocular symptoms of COVID-19 
with their relation to the presenting systemic manifestation 
along with its severity level.
METHODS
Literature search strategy
We performed a systematic review according to Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
(PRISMA) guideline.12 Literature search was conducted 
from 4 to 9 June 2020 using three electronic databases: 
PubMed, ScienceDirect and Google Scholar. The liter-
ature search would be expanded using a snowballing 
method to the references of retrieved papers. Articles 
were identified with search strategy: “SARS- CoV-2 [supple-
mentary concept]” OR “2019- nCoV” OR “COVID-19 
[supplementary concept]” AND “conjunctiv*” OR “eye 
manifestations (MeSH)” OR “cornea (MeSH)” OR 
“ocular surface” OR “dry eye syndromes (MeSH)”. This 
study was registered to the International Prospective 
Register of Systematic Reviews (PROSPERO registration 
number CRD42020194245).
Eligibility criteria
The enrolment date of studies was restricted from December 
2019 to 1 June 2020. Records were managed by Mendeley 
software to exclude duplicates. Articles in English and 
human subjects were obtained. The inclusion criteria were 
(1) peer- reviewed observational case series and case report 
studies of COVID-19- related patients, including confirmed 
and suspected cases; (2) studies providing ocular manifes-
tations; (3) if available, studies reporting PCR positivity 
in either ocular, elsewhere samples or both. Studies that 
reported ocular involvement but did not describe the ocular 
manifestations or reported only subjective ocular complaints 
were excluded. If it is necessary, the original author of each 
study was contacted by email to request further information.
Data extraction
Three authors (RLDN, IS and DFK) independently 
reviewed titles and abstracts generated by the search. 
A standardised data abstraction table was designed to 
capture all relevant information required for analysis. 
For all included studies, we recorded the following infor-
mation: author, date of publication, study design, PCR 
positivity in nasal swab and tears, the onset of ocular 
manifestation, description of ocular and systemic mani-
festations, and disease severity. Ocular symptom duration 
and treatment given by the healthcare providers were 
also noted whenever the data are available.
Quality assessment
Two authors independently assessed the quality of 
included studies (DFK and ASR). The risk of bias and 
quality of primary studies or systematic reviews were 
assessed using the Newcastle- Ottawa Scale for longitu-
dinal and cross- sectional studies.13 The quality levels then 
were graded as good, fair or poor. For case series and 
case report studies, the quality was assessed using Murad 
et al’s14 set of criteria and graded as poor, moderate r 
good quality. Discrepancies and disagreements were 
resolved by consensus, and/or resolution of the conflict 
was performed by a third reviewer (IP) if necessary.
Patient involvement
Patients were not directly involved in the design of this 
study.
Statistical analysis
We undertook an initial descriptive analysis of the studies. 
The heterogeneity between estimates was assessed using 
the I2 statistic. For studies with calculable prevalence 
for each item, the meta- analysis was performed using a 
random- effects model conducted using the MetaXL 5.3 ( 
www. epigear. com) add- in for Microsoft Excel Professional 
Plus 2013. A pooled prevalence figure was calculated 
with a 95% CI. The pooled OR for the association of 
ocular manifestation with COVID-19 severity was calcu-
lated using a random model effect. The Mantel- Haenszel 
method was used to weight the studies. This statistical 
approach was performed using Review Manager V.5.4.
RESULTS
Study selection
Our initial search identified 31 studies to be analysed 
qualitatively in our systematic review. There were 5 
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longitudinal, 9 cross- sectional, 5 case series, and 12 case 
report studies being reviewed for analysis. For quantita-
tive analysis, 14 studies could be included in the pooled 
meta- analysis of prevalence. The flowchart of study selec-
tion is illustrated in figure 1. All articles were assessed 
for validity (online supplemental file). Tables 1 and 2 
summarise the characteristics and main findings of the 
observational and case report studies, respectively.
Ocular manifestation and PCR positivity rate for SARS-CoV-2 
among COVID-19-related patients
A meta- analysis to determine the estimation of ocular 
manifestation among COVID-19- related patients 
was performed. The pooled prevalence of ocular 
manifestation among COVID-19- related patients was 0.05 
(0.02%–0.08 95% CI). The I2 for heterogeneity test was 
86%, suggesting a high level of heterogeneity (figure 2). 
Most of the studies with a large number of patients 
(Guan et al,7 Wu et al8 and Zhang et al15) included patients 
already admitted to the hospital. In addition, most of 
the studies included in this study reported only ocular 
complaints from their subjects without any further ocular 
examination.
From COVID-19- related patients with ocular manifes-
tations, overall PCR positivity from tears samples was 0.38 
(95% CI 0.14% to 0.65, figure 3). The pooled PCR posi-
tivity from tears was higher compared with general PCR 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses flowchart for the study selection process.
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tears positivity from all COVID-19- related patients. If all 
available data of PCR positivity from tears were combined 
regardless of the presence of ocular manifestation, the 
pooled PCR positivity was only 0.04 (95% CI 0.02% to 
0.07, figure 4).
Relationship between the onset of ocular symptoms with the 
systemic manifestation of COVID-19
Several studies had reported the onset of ocular symptoms 
in relation to the presence of any systemic manifesta-
tion. From the pooled analysis, 0.28 (95% CI 0.05% to 
0.58, figure 5) of ocular manifestation appeared without 
any systemic manifestations noticed by the patients. 
Frequent touching of the eyes with hands,16 elderly 
(age >60 years),17–19 immunosuppression,17 lacrimal 
duct abnormalities,17 swimming20 and being healthcare 
workers6 21 were reported to be possible predisposing 
factors for ocular manifestation of COVID-19.
Ocular manifestation can occur before, parallel or 
after the presence of systemic manifestation. Based on 
Scalinci et al’s22 report, conjunctivitis could be the only 
manifestation of COVID-19 without any subsequent 
systemic manifestation. Interestingly, they found that the 
nasopharyngeal swab yielded a positive result in all of 
these patients.22 In another study, Cheema et al20 found 
that when the ocular and systemic manifestation occurred 
at the same time in the early stage of the disease, PCR 
samples from both tears and nasopharyngeal mucosa 
could be positive. Moreover, they found that the cycle 
threshold for tears sample had a weaker signal compared 
with a nasopharyngeal swab.20 From the case series and 
case report studies, we found that the method and cycle 
threshold for PCR testing might influence the positivity 
rate of tear samples. Chen et al23 and Hu et al17 took tear 
samples through putting sterile synthetic fibre or cotton 
swabs into the lower fornix of each eye with or without 
topical anaesthesia and found that this yielded a positive 
result, whereas Seah et al24 took the tears samples with 
Schirmer strips and found that none of the samples was 
positive for SARS- CoV-2 even in the patient with conjunc-
tivitis.
Figure 2 Forest plot estimating the pooled prevalence of ocular manifestation among COVID-19- related patients.
Figure 3 Forest plot estimating the pooled prevalence of PCR tears (+) among COVID-19- related patients with ocular 
manifestation.
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Severe COVID-19 was not associated with the presence 
of ocular manifestation (figure 6). A study by Navel et 
al25 found haemorrhagic conjunctivitis in an intubated 
patient with COVID-19 after several days of hospitalisa-
tion. However, PCR testing yield negative for SARS- CoV-2 
even after excluding other potential microorganisms that 
could contribute to the ocular manifestation.25
DISCUSSION
Our systematic review and meta- analysis found a low 
prevalence of ocular manifestation in COVID-19- related 
patients. We also found that general PCR positivity from 
ocular samples was very low. However, when patients 
with COVID-19 had ocular manifestation, the positivity 
rate increased. The most common ocular manifestation 
being reported was epiphora, conjunctival injection and 
chemosis, similar to the other form of viral conjunctivitis 
with follicular reaction.
Our findings were in accordance with the previous 
systematic review by Aiello et al26 that available earlier. Most 
of the studies included in their review were also included 
in our current study. In addition, we further performed a 
meta- analysis and elaborate on the association of ocular 
manifestation with the systemic manifestation of COVID-
19. Also, we added the data from case series and reports 
of individual patients with COVID-19 that explain the 
time course and disease severity of COVID-19 among 
those presenting with ocular manifestation.
The ocular surface can be the window of SARS- CoV-2 
entry to the human body as the ACE-2 receptor found 
in conjunctiva and cornea. The TMPRSS2 protease 
activity also appeared in the ocular surface.9 27 Recent 
work by Zhou et al28 and Collin et al29 found that ACE-2 
receptor and TMPRSS2 are highly found in the ocular 
surface epithelium, which can be the entry portal of 
coronavirus. Inflammation milieu could potentiate 
upregulation of ACE-2 and TMPRSS2.29 As the virus 
may replicate after the ocular surface is being infected 
by the SARS- CoV-2, the virus can cause ocular manifes-
tation prior to any systemic symptoms. Although most 
of the ocular manifestation being reported was asso-
ciated with red eyes, a case report by Hu et al17 found 
that SARS- CoV-2 could be found in tears of asymptom-
atic eyes. In this case, further evaluation revealed a 
nasolacrimal duct obstruction. Even after the nasopha-
ryngeal swab had turned negative, the tears were still 
found to be positive with low signal.17 Another report 
among paediatric patients with COVID-19 asymptom-
atic of ocular manifestation showed that their tears 
could also be positive for SARS- CoV-2.30 Moreover, it 
was noted that patients with only ocular manifesta-
tion could have nasopharyngeal mucosa positive for 
Figure 4 Forest plot estimating the pooled prevalence of PCR tears (+) among all COVID-19- related patients.
Figure 5 Forest plot estimating the pooled prevalence of ocular manifestation before any systemic manifestation among 
COVID-19 related patients with ocular manifestation.
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SARS- CoV-2.22 It raises the possibility that infection 
of COVID-19 in the eyes could lead to systemic mani-
festation via either nasolacrimal duct or touching the 
nose by hands contaminated with the virus from tears. 
Second, it may implicate that patients with ocular 
manifestation presenting with viral conjunctivitis- 
like symptoms can be a source of transmission of 
SARS- CoV-2 to the population or unaware healthcare 
professionals. The possibility of the virus being trans-
ported to the nasopharynx was previously described, 
and it can occur experimentally in N95 respirator use 
without eye protection.11 31
We found that the ocular manifestation was not 
associated with a severe form of COVID-19. However, 
subtle laboratory values may differ between patients 
with and without ocular manifestation. Two previous 
initial meta- analyses found the discrepancy of the 
evidence whether ocular manifestation could attri-
bute to a severe form of COVID-19.32 33 Loffredo et 
al33 found that conjunctivitis among patients with 
COVID-19 was significantly associated with severe 
COVID-19. However, the conclusion was based only 
on three studies. As our study added more available 
data, we found the severity of COVID-19 was not asso-
ciated with the ocular manifestation. From Wu et al’s8 
study, patients with COVID-19 presenting with ocular 
involvement had higher white blood cells, procalci-
tonin, C reactive protein and lactate dehydrogenase. 
Further evaluation needs to be done to confirm this 
finding. The severity of COVID-19 was probably mainly 
attributed to other systemic risk factors and the age of 
the patients.
Although we found that there was no significant 
ocular manifestation related to posterior segment 
abnormalities, the possible retinal involvement 
had been reported in patients with COVID-19. The 
ACE-2 receptor had also been reported in the human 
retina.34 Based on retinal biopsy specimens from 12 
patients with COVID-19 who died, three specimens 
showed positive SARS- CoV-2 RNA with a weak signal. 
There was no report about any previous ocular 
manifestations until these patients died. However, 
the viral replication was not performed from these 
samples.35 Interestingly, Marinho et al36 reported 
recent ocular coherence tomography examination 
of COVID-19- related patients without any ocular 
manifestation. They found a subclinical change in 
ganglion cells and inner plexiform layers among these 
patients.36 Thus, ophthalmologists should be careful 
if they found this subtle change in OCT unintention-
ally or if they face patients with visual deterioration 
without typical of ocular surface manifestation of 
COVID-19- related patients.
Collecting adequate tears specimen for PCR testing 
may be a challenge in determining the true magnitude 
of ocular manifestation directly caused by SARS- CoV-2. 
We found a discrepancy in the result of PCR posi-
tivity of SARS- CoV-2 in tears by the methods of tear 
sampling. Seah et al24 found Schirmer strip to obtain 
the virus and could not prove any positive result, even 
in patients with COVID-19 with conjunctivitis. Because 
of the high cycle threshold for detecting the presence 
of SARS- CoV-2 in tears compared with nasopharyngeal 
swab,10 the sampling method could potentially deter-
mine the positivity rate. Previously, Satpathy et al37 and 
Ma et al 38 found that scrapping specimen yielded a 
better PCR positivity rate compared with tears spec-
imen based on the analysis of ocular herpes simplex 
cases. As described in a study evaluating nasal swab 
and aspirates, the quality of the samples for optimal 
virological diagnosis should be rich in cells. The more 
cells obtained, the more accurate the diagnosis. Even 
if there is no standardised minimum amount of cells 
for virological detection, this might apply in ocular 
samples for SARS- CoV-2 detection.39
Based on our findings, ophthalmologists should be 
aware of the possibility that patients may present only 
with viral conjunctivitis due to SARS- CoV-2 infection 
and may develop systemic manifestation several days 
later. Around one- third of patients who presented with 
ocular manifestation had signs and symptoms before 
they develop systemic COVID-19 manifestation. More-
over, around a third of COVID-19 related patients with 
ocular manifestations had SARS- CoV-2 PCR positive from 
the eye samples which could be infectious, although the 
infectivity of ocular samples yet to be determined.40 For 
hospitalised COVID-19 patient, any red eyes should be 
suspicious for the ocular manifestation of COVID-19 
until proven otherwise. However, to our knowledge, there 
was no sight- threatening ocular condition found among 
Figure 6 Forest plot estimating the OR of ocular manifestation in relation to severe COVID-19.
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COVID-19 patients that directly attributed to SARS- CoV-2 
infection in the eyes. Moreover, the treatment option was 
varied across studies, ranging from artificial tears to anti-
viral eyedrops (tables 1 and 2). The ocular manifestation 
could improve in all studies without any complication. 
Urgent consultation with an ophthalmologist may not be 
needed as long as the ocular manifestation does not get 
worse during the treatment course. For the ophthalmol-
ogist facing viral conjunctivitis- like patients without any 
systemic manifestation but high risk of being infected 
with SARS- CoV-2, it is reasonable if the tears specimen for 
PCR testing could be obtained in a repeated manner or in 
combination with the nasopharyngeal swab. Performing 
routine PCR testing for SARS- CoV-2 among patients with 
COVID-19 without ocular manifestation may yield a very 
low positivity rate, as previously reported by Deng et al.41 
Eye protection and mask should be worn in managing 
patients with red eyes in daily clinical practice. A recent 
systematic review found that using eye protection or face 
mask, in addition to physical distancing and using respi-
rators, could further reduce the risk of being infected by 
SARS- CoV-2.42
This study had several limitations. First, the general 
positivity rate of ocular samples for SARS- CoV-2 esti-
mated mostly by studies conducting in hospital 
settings. This value can be overestimated. Second, the 
description of onset and ocular manifestation varies 
between studies included. Also, most of the studies did 
not describe in detail how to obtain tear samples. As 
we previously mentioned, the technique possibly influ-
ences the positivity rate. Subgroup analysis of pooled 
prevalence could not be performed further as the data 
for ocular manifestations were limited. Language bias 
may also be of relevance in this systematic review.
CONCLUSIONS
After carefully reviewing the available literature, we found 
that ocular manifestation can be the first presenting 
symptom of COVID-19. Eye infection of SARS- CoV-2 
could potentially lead to systemic manifestation, although 
its evidence needs further investigation. Patients with 
COVID-19 with ocular manifestation were not associ-
ated with severe COVID-19. Detecting SARS- CoV-2 from 
tears yielded a relatively low positivity rate. However, we 
acknowledged the possibility of SARS- CoV-2 transmission 
from patients with COVID-19 presenting with only ocular 
manifestation.
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